Small Cell Lung Cancer Recurrent Clinical Trial
Official title:
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer：An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)
The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.
Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease.These patients have a median survival of only 4 to 5 months when treated with further systemic therapy. Improvements in therapy for relapsed SCLC are much needed.The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05815160 -
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
|
Phase 1 | |
| Recruiting |
NCT03262454 -
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
|
Phase 2 | |
| Terminated |
NCT02477813 -
Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation
|
Phase 2 | |
| Not yet recruiting |
NCT06258642 -
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
|
N/A | |
| Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01441297 -
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT03994744 -
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
|
Phase 2 |